Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to STADA for ~$660M

 Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to STADA for ~$660M

Takeda to Divest its Portfolio of Select OTC and Non-Core Assets to STADA for ~$660M

Shots:

  • Takeda to receive ~$660M for divesting its 20 select prescription pharmaceutical and OTC products traded in Russia, Georgia, and several countries within the Commonwealth of Independent States. STADA to get rights, title, and interest to the products in the portfolio exclusive in these countries. The transaction is expected to close in Q4’19
  • Additionally, Takeda and STADA will sign manufacturing and supply agreement under which Takeda will continue to manufacture the products on behalf of STADA
  • The divestiture allows Takeda to focus on its five key business areas, accelerating its deleveraging following its acquisition of Shire. The portfolio to be divested includes OTC vitamins and food supplement and select products within CV, diabetes, general medicine, and respiratory therapeutic areas

Click here to­ read full press release/ article | Ref: Takeda | Image: Takeda

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post